Octapharma Accepting Applications for Research Grants Focused on Human Protein Therapies
HOBOKEN, N.J., Oct. 14 /PRNewswire/ -- Octapharma USA is accepting applications for the Octapharma 25th Anniversary Grants Program, which supports clinical or pre-clinical research focused on human protein therapies in coagulation disorders, immune therapy, intensive care and emergency medicine. The application deadline is April 1, 2011.
Octapharma AG, one of the largest human protein products manufacturers in the world, launched the Octapharma Grants program last year in celebration of the biopharmaceutical company's 25th anniversary. The company's first ever grants program is only available to researchers based in the United States and is administered by Octapharma USA.
Earlier this year, the Rush Hemophilia & Thrombophilia Center at Rush University Medical Center in Chicago was awarded the first grant in the Octapharma program to support research into blood induced joint damage in hemophilia.
Grant applications are accepted online only at www.octapharmagrants.com. All grant requests will be evaluated by the Octapharma Grants Committee and grant recipients will be announced shortly afterward. Please visit www.octapharmagrants.com for a complete description of the grants program, including the application and review process.
About the Octapharma Group
Headquartered in Lachen, Switzerland, Octapharma AG is one of the largest human protein products manufacturers in the world and has been committed to patient care and medical innovation for